Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
The PROTECT Trial for IgAN Patients
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Brief Description
This study will be a randomized, active-control study that will help to determine if Sparsentan is effective at improving symptoms of IgAN.
Trial Physician / Study Coordinator
Cheuk Yiu, Rebecca Law
EmailSite Name
Yan Chai Hospital
Room 526, 5/F, Block A, Yan Chai Hospital, 7-11 Yan Chai Street, Tsuen Wan, Hong Kong
Sponsor
Travere Therapeutics
Study Drug
Sparsentan
Estimated enrollment
280
Estimated end date
April 2023
Interventional Study
a clinical trial in which a new drug or device is used to measure a specific outcome.
The PROTECT Trial for IgAN Patients
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Brief Description
This study will be a randomized, active-control study that will help to determine if Sparsentan is effective at improving symptoms of IgAN.
Trial is for people with
IgA Nephropathy (IgAN)
Study Goal
To evaluate the potential benefit of Sparsentan on kidney function by analyzing change in proteinuria (protein in urine) and estimated glomerular filtration rate (eGFR) as compared to current standard treatment.
What is involved for the Patient?
Patients will take a daily dose of the study medication, and will be involved with the trial for about 2 years.
About the drug or intervention
Sparsentan is a tablet taken orally.